Clinical Scope
An honest view of where rTMS has established evidence versus where it remains an emerging research area. Suitability can only be confirmed through a full psychiatric assessment.
Repetitive transcranial magnetic stimulation is an established, guideline-recognised treatment option for depressive disorders.
rTMS is supported by randomised evidence, regulatory clearances in multiple jurisdictions and international guidance for adults with depression. It is most often considered when medication has not produced adequate improvement, has been poorly tolerated, or when patients prefer a non-medication option.
rTMS is one of the best-evidenced non-pharmacological options for depression that has not responded to earlier treatments.
Treatment resistance is usually assessed by the number of adequate medication trials tried without sufficient benefit. The evidence for rTMS is strongest in this group, and treatment decisions should be individualised through specialist assessment.
Regulatory clearance exists in some jurisdictions for specific deep TMS protocols in OCD; availability and protocols must be verified locally.
In 2018 the US FDA cleared a specific deep transcranial magnetic stimulation system as an adjunct for obsessive-compulsive disorder in adults, based on a randomised controlled trial. Evidence is evolving, protocols differ from depression protocols, and device-specific clearances do not automatically apply to every system or setting. Suitability must be assessed case by case.
rTMS is being studied for many other conditions; this research is not equivalent to established clinical treatment.
Investigational uses under study include anxiety disorders, substance-use disorders and neurological populations, among others. Findings are mixed and protocols vary. Any discussion of investigational applications takes place within research frameworks or carefully documented off-label clinical pathways, with full transparency about the current evidence.